Back to discover
Drug

ChAdOx1 nCoV-19

In clinical development
Emerging researchLate-stage development

Also known as AstraZeneca COVID-19 Vaccine, Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19, SARS-CoV-2 (COVID-19) ChAdOx1 vaccine, recombinant, SARS-CoV-2 ChAdOx1 vaccine, recombinant.

RxNorm2360598UNIIB5S3K2V0G8
4
Research papers
1
Active clinical trials
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

A Phase 2/3 Study to Determine the Efficacy, Safety and Immunogenicity of the Candidate Coronavirus Disease (COVID-19) Vaccine ChAdOx1 nCoV-19

Clinical trial2025-02-05Completed · ClinicalTrials.gov

A Phase I/II Study to Determine Efficacy, Safety and Immunogenicity of the Candidate Coronavirus Disease (COVID-19) Vaccine ChAdOx1 nCoV-19 in UK Healthy Adult Volunteers

Clinical trial2025-02-05Completed · ClinicalTrials.gov

Immunogenicity and Adverse Events Following Immunization (AEFI) With Alternate Schedules of COVID-19 Vaccines in Canada: is "Mix and Match" of the Second Dose (MOSAIC-1;CT24a) and Additional Doses (MOSAIC-2 and MOSAIC-3;CT24b and CT24c) Safe and Immunogenic?

Clinical trial2024-11-15Primary completion · ClinicalTrials.gov

A Phase III, Randomized, Observer-blind, Active-controlled, Parallel-group, Multi-center Study to Evaluate Immunogenicity and Safety of a Preventive COVID-19 Vaccine EuCorVac-19 in Healthy Adults Aged 18 Years and Older

Clinical trial2024-02-09Completed · ClinicalTrials.gov

A Phase III, Randomized, Observer-blind, Active-controlled, Parallel-group, Multi-center Study to Evaluate Immunogenicity and Safety of a Preventive COVID-19 Vaccine EuCorVac-19 in Healthy Adults Aged 18 Years and Older

Clinical trial2024-01-15Completed · ClinicalTrials.gov

Phase II/III Parallel, Double-blind, Non-inferiority Study With Active Control, to Evaluate the Immunogenicity and Safety of a Booster Immunization Scheme With a Single Intramuscular Dose of the Recombinant Vaccine Against SARS-CoV-2

Clinical trial2023-09-10Completed · ClinicalTrials.gov

Tracking the COVID-19 vaccines: The global landscape.

Research2023-03-30Human vaccines & immunotherapeutics

Viral Vectors in Gene Therapy: Where Do We Stand in 2023?

Research2023-03-07Viruses

A Phase I Study to Determine Safety, Tolerability and Immunogenicity of Intranasal Administration of the COVID Vaccine ChAdOx1 nCOV-19 in Healthy UK Adults

Clinical trial2022-09-30Completed · ClinicalTrials.gov

Assessment of the Immunogenicity and Safety of Marketed Vaccines for COVID-19 After Regular Schedule and Adapted Vaccine Schedules and Routes: BNT162b2, mRNA-1273 Vaccine and ChAdOx1-S [Recombinant]

Clinical trial2022-07-08Completed · ClinicalTrials.gov

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

Research2020-12-08Lancet (London, England)

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.

Research2020-11-19Lancet (London, England)

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
ChAdOx1 nCoV-19
Aliases & brands
AstraZeneca COVID-19 VaccineCoronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19SARS-CoV-2 (COVID-19) ChAdOx1 vaccine, recombinantSARS-CoV-2 ChAdOx1 vaccine, recombinant
RxNorm CUI
2360598
UNII
B5S3K2V0G8

Clinical trials

9 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
9
registered trials across all phases
LATEST COMPLETION 2025
1
Active studies
5
Late-stage (III+)
7
Completed
1
Discontinued
PHASE DISTRIBUTIONn = 9
Phase 11Phase 1 / 22Phase 21Phase 2 / 32Phase 32Phase 41

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Assessment of the Immunogenicity and Safety of Marketed Vaccines for COVID-19 After Regular Schedule and Adapted Vaccine Schedules and Routes: BNT162b2, mRNA-1273 Vaccine and ChAdOx1-S [Recombinant]

CompletedPH IVUniversiteit Antwerpenn=5802022

A Phase 2/3 Study to Determine the Efficacy, Safety and Immunogenicity of the Candidate Coronavirus Disease (COVID-19) Vaccine ChAdOx1 nCoV-19

CompletedPH II/IIIKey trialUniversity of Oxfordn=10,8112025

A Phase III, Randomized, Observer-blind, Active-controlled, Parallel-group, Multi-center Study to Evaluate Immunogenicity and Safety of a Preventive COVID-19 Vaccine EuCorVac-19 in Healthy Adults Aged 18 Years and Older

CompletedPH IIIKey trialEuBiologics Co.,Ltdn=2,6002024

A Phase III, Randomized, Observer-blind, Active-controlled, Parallel-group, Multi-center Study to Evaluate Immunogenicity and Safety of a Preventive COVID-19 Vaccine EuCorVac-19 in Healthy Adults Aged 18 Years and Older

CompletedPH IIIKey trialEuBiologics Co.,Ltdn=2,8522024

Phase II/III Parallel, Double-blind, Non-inferiority Study With Active Control, to Evaluate the Immunogenicity and Safety of a Booster Immunization Scheme With a Single Intramuscular Dose of the Recombinant Vaccine Against SARS-CoV-2

CompletedPH II/IIIKey trialLaboratorio Avi-Mex, S.A. de C.V.n=4,0652023

Recent completions

Trials that read out recently, adding to the completed evidence base.

A Phase I/II Study to Determine Efficacy, Safety and Immunogenicity of the Candidate Coronavirus Disease (COVID-19) Vaccine ChAdOx1 nCoV-19 in UK Healthy Adult Volunteers

CompletedPH I/IIUniversity of Oxfordn=1,0772025

A Phase 2/3 Study to Determine the Efficacy, Safety and Immunogenicity of the Candidate Coronavirus Disease (COVID-19) Vaccine ChAdOx1 nCoV-19

CompletedPH II/IIIKey trialUniversity of Oxfordn=10,8112025

A Phase III, Randomized, Observer-blind, Active-controlled, Parallel-group, Multi-center Study to Evaluate Immunogenicity and Safety of a Preventive COVID-19 Vaccine EuCorVac-19 in Healthy Adults Aged 18 Years and Older

CompletedPH IIIKey trialEuBiologics Co.,Ltdn=2,6002024

A Phase III, Randomized, Observer-blind, Active-controlled, Parallel-group, Multi-center Study to Evaluate Immunogenicity and Safety of a Preventive COVID-19 Vaccine EuCorVac-19 in Healthy Adults Aged 18 Years and Older

CompletedPH IIIKey trialEuBiologics Co.,Ltdn=2,8522024

Phase II/III Parallel, Double-blind, Non-inferiority Study With Active Control, to Evaluate the Immunogenicity and Safety of a Booster Immunization Scheme With a Single Intramuscular Dose of the Recombinant Vaccine Against SARS-CoV-2

CompletedPH II/IIIKey trialLaboratorio Avi-Mex, S.A. de C.V.n=4,0652023

A Phase I Study to Determine Safety, Tolerability and Immunogenicity of Intranasal Administration of the COVID Vaccine ChAdOx1 nCOV-19 in Healthy UK Adults

CompletedPH IUniversity of Oxfordn=422022

Research activity

4 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
20212023
Major research themes5
COVID-19 Vaccines2COVID-191Genetic Therapy1Genetic Vectors1Immunogenicity, Vaccine1
Journals, researchers & institutions
Top journals
  • Lancet (London, England)2
  • Human vaccines & immunotherapeutics1
  • Viruses1
Leading researchers
  • Aley PK2
  • Angus B2
  • Bibi S2
  • Cicconi P2
  • Colin-Jones R2
  • Douglas AD2
  • Emary KRW2
  • Ewer KJ2
Leading institutions
free-text, unnormalised
  • NIHR Southampton Clinical Research Facility and Biomedical Research Centre2
  • University of Oxford2
  • and Oxford Centre for Clinical Tropical Medicine and Global Health1
  • Braziland Hospital São Rafael1
  • Centre for Advanced Research (CFAR)1
  • Clinical Biomanufacturing Facility1

Related diseases

1 conditions

Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.

Active research areas
COVID-193

Related drugs

2 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Ad26COVS1

Studied across 3 of the same disease areas as ChAdOx1 nCoV-19 in the shared literature.

3 shared diseases2 shared papers
COVID-19 Vaccines

Studied across the same disease area as ChAdOx1 nCoV-19 in the shared literature.

1 shared disease3 shared papers
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials